Nvidia, Eli Lilly to Spend $1 Billion on Joint Lab That Will Use Nvidia Vera Rubin AI Chips
THOMSON REUTERS
Jan 12
Nvidia Corporation and Eli Lilly and Company have announced the creation of a first-of-its-kind AI co-innovation lab aimed at transforming drug discovery through artificial intelligence. The two companies will jointly invest up to $1 billion over five years in infrastructure, talent, and research.
The lab, based in the San Francisco Bay Area, will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture, combining Lilly’s expertise in medicine with Nvidia’s strengths in AI and accelerated computing. The collaboration will focus on developing advanced AI models and robotics to accelerate and scale the discovery and production of new medicines.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.